Search Results - "Mortaruolo, C."

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
  2. 2

    Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma by Picardi, M., Della Pepa, R., Giordano, C., Pugliese, N., Mortaruolo, C., Trastulli, F., Rascato, M.G., Cappuccio, I., Raimondo, M., Memoli, M., Monteverde, M., Mascolo, M., Pane, F.

    Published in Blood advances (14-05-2019)
    “…We evaluated the impact on progression-free survival (PFS) of achieving a deep metabolic response at 2-deoxy-2[18F] fluoro-d-glucose positron emission…”
    Get full text
    Journal Article
  3. 3

    PB1801 PRIMARY EXTRA‐NODAL DIFFUSE LARGE B‐CELL LYMPHOMA: A RETROSPECTIVE SINGLE INSTITUTE ANALYSIS ON TREATMENT MODALITIES AND OUTCOME by Giordano, C., Giordano, A., Pugliese, N., Della Pepa, R., Rascato, M.G., Fatigati, C., Mortaruolo, C., Mascolo, M., Picardi, M., Pane, F.

    Published in HemaSphere (01-06-2019)
    “…Background: Extranodal lymphomas comprise around 30% of Non‐Hodgkin lymphomas (NHL) and the majority are diffuse large B‐cell lymphomas (DLBCL). The exact…”
    Get full text
    Journal Article